genomes.io
Genomes.io is a UK-based decentralized genomic data platform that lets consumers store 30x whole-genome sequences in SEV-ES encrypted vaults and run polygenic risk reports, while selling Virtual Labs to pharma, biotech and research organizations to query consented data.
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What genomes.io does
Genomes.io (legal entity Genomesio LTD, also branded as GenomesDAO) is a London-based, UK-registered private company founded in 2018 that operates a decentralized genomic data platform combining AMD SEV-ES encrypted "DNA Vaults" with an Ethereum blockchain audit log and a Base-blockchain-based $GENOME utility token. Its core product is a user-controlled vault: individuals can either purchase 30x whole-genome sequencing kits routed through partner laboratories (Dante Genomics, Nebula Genomics; Dante currently listed as temporarily unavailable) or upload existing raw data from 23andMe, MyHeritage, or Ancestry.com into the same vault. Once vaulted, users can run a library of genetic reports covering ancestry, carrier status, health risks, and pharmacogenetics, gated by an iOS/Android authenticator app that mediates access.
The company operates a hybrid GTM motion. Direct-to-consumer revenue is generated from £399 sequencing kit sales (non-refundable, sourced from sequencing partners) and a £199 lifetime subscription that unlocks 50+ polygenic risk assessments and single-variant analyses. A points-based referral program and a $GENOME/$KIT token staking layer (50% APY, redeemable for kits) add a crypto-native growth and retention mechanic. Enterprise revenue is targeted at pharmaceutical, biotechnology, contract research, academic, and patient-organization buyers through "Virtual Labs," which let organizations build custom reports and run query-based research against consented vault data, with the company positioning itself as a compliant (CLIA/CAP partner labs, GDPR/CCPA) intermediary.
Genomes.io has raised approximately $21.6M+ in disclosed funding, including a $20M GEM Digital investment in August 2023 and a June 2024 round co-led by Pantera Capital and Modular Capital, alongside earlier Crowdcube raises. It has partnerships with AMD (encryption), Consensys (Tachyon accelerator and Base ecosystem), and its sequencing providers. The company is led by co-founders Dr. Mark Hahnel (CSO), Aldo de Pape (CEO), and Chris Griffiths (COO), and operates with 11–50 employees. Revenue is not publicly disclosed.
genomes.io firmographics
Firmographics- Name
- genomes.io
- Legal name
- Genomesio LTD
- Website
- https://genomes.io
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genomes.io is a UK-based decentralized genomic data platform that lets consumers store 30x whole-genome sequences in SEV-ES encrypted vaults and run polygenic risk reports, while selling Virtual Labs to pharma, biotech and research organizations to query consented data.
- Ownership category
- akta.pro rank
genomes.io industry classification
Industry- Product category
- Genomic Data Platform
- NAICS
- Medical Laboratories (621511), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Population Genomics & Preventive Precision Health Programs (HLAAANAL)
Keywords
Where genomes.io is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
genomes.io business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- DNA Sequencing Kit Sales: Users purchase 30x whole genome sequencing kits from partnered providers (Dante Genomics, Nebula Genomics) through the platform. Revenue realized at point of purchase with no refunds.
- Lifetime Subscription for Reports: One-time lifetime subscription (£199) granting access to all genetic reports including 50+ polygenic risk assessments and single-variant analyses.
- $GENOME Token Rewards: Users earn $GENOME tokens for uploading DNA data, referring friends, and running health reports. Token can be traded for sequencing kits, genomic insights, or fiat.
- $KIT Staking Program: $KIT is a utility token redeemable for genome sequencing kits (valued at $300). Users stake $GENOME to earn $KIT at 50% APY.
- Virtual Lab Enterprise Services: Organizations (pharma, biotech, research institutions) pay for customized virtual labs enabling genomic research with secure data access, custom report development, and payment systems for receiving query rewards.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Dante Genomics 30x Whole Genome Sequencing |
| One time/ perpetual license | Pay-as-you-go | Lifetime Subscription - All Reports |
| Freemium | Pay-as-you-go | Free Reports (Carrier Status) |
| Transaction based/ take rate | Annual | $GENOME Staking Rewards |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels8 records
genomes.io product offering
Product offeringCore offering
Genomes.io operates a decentralized genomic data platform that lets individuals store, manage, and monetize their DNA through SEV-ES encrypted vaults. Users can either purchase 30x whole genome sequencing through partner labs or upload existing raw DNA files from 23andMe, MyHeritage, or Ancestry.com. Pharmaceutical, biotech, and academic organizations access verified, consent-based genomic datasets through the Virtual Labs portal to run research studies against encrypted, user-owned data.
Product overview
Genomes.io is a decentralized genomic data platform built on blockchain technology, offering a suite of products centered around user-owned genomic data control. The core product is the DNA Vault using SEV-ES encryption where users securely store their genomic data. Users can either get sequenced through 30x Whole Genome Sequencing (via partner labs Dante Genomics and Nebula Genomics) or upload existing data from 23andMe, MyHeritage, or Ancestry.com. The Genetic Reports module provides 50+ polygenic risk assessments and single-variant analyses. For enterprise customers, Virtual Labs enables pharmaceutical and research organizations to query genomic databases with participant consent. The $GENOME token powers a reward system where users earn tokens for data contributions, with staking via the $KIT token providing 50% APY. The Genomes.io Authenticator mobile app provides user-controlled access management to DNA Vaults.
Differentiator
Problem solved
Functional benefit
Brands
- Virtual Labs: Customised virtual labs for organizations advancing genomics research, allowing development of custom reports, bespoke vault environments, and payment systems for research queries.
Products and services
- DNA Vault
Quantifiable outcome
- Reads all 3 billion base pairs at 30x coverage vs genotyping reading only 0.002% or exome sequencing reading 1.5%
- +1 more outcomes
Companies that use genomes.io
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles2 records
genomes.io technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability3 records
Feature7 records
genomes.io partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered key and core.
- AMDkeyCollaboration to bring state-of-the-art encryption technology to genomic data storage. First-of-its-kind innovation partnership for enhanced data security.
- ConsensyskeyGenomes.io was part of the Consensys Incubator Tachyon program, gaining access to global web3 ecosystem and blockchain expertise.
- Dante GenomicscoreCAP accredited and CLIA compliant 30x whole genome sequencing provider. Provides end-to-end privacy-preserving workflows with data uploaded directly to user DNA Vaults. Currently listed as temporarily unavailable.
- Nebula GenomicscoreSequencing provider offering 30x whole genome sequencing with 14-week turnaround. Sample return address: 711 Stewart Ave, Suite 200, Garden City, NY 11530, USA.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
genomes.io competitors and assessment
Company assessmentDirect peers
- Nebula Genomics: Founded by George Church, Nebula Genomics offers 30x whole-genome sequencing with a privacy-focused, user-controlled data model on blockchain. Direct D2C competitor and current sequencing partner for Genomes.io, sharing both product positioning and technology stack philosophy.
- Dante Genomics: Global whole-genome sequencing provider offering 30x WGS with CLIA/CAP compliance and direct-to-consumer reports. Currently a sequencing partner for Genomes.io but also a competitive D2C sequencing option for the same consumer.
- Veritas Genetics: Whole-genome sequencing provider offering clinical and consumer-grade WGS with health-risk reporting. Overlaps with Genomes.io on sequencing depth, report library, and D2C positioning.
- Sequencing.com: Genetic data platform offering app marketplace and report ecosystem atop user-uploaded DNA data. Closely comparable business model to Genomes.io's vault-plus-reports approach, including support for uploads from major testing services.
Broad incumbents
- 23andMe: Largest consumer genetic testing brand with tens of millions of genotyped users, ancestry and health reports, and a therapeutics pipeline. Competes for the same health-conscious consumer and is a data-source integration for Genomes.io's upload feature.
- Ancestry.com: Dominant consumer genealogy platform with the largest autosomal DNA database and integrated family-tree product. Competes for consumer attention in genetic insights and is an upload integration for Genomes.io.
- MyHeritage: Global consumer DNA testing and genealogy platform with strong European footprint. Competes in the same D2C genetic-testing category and is also an upload integration source for Genomes.io's vault.
Emerging players
- Color Genomics: Clinical-grade genetic testing company focused on hereditary cancer, pharmacogenomics, and population-health programs for employers and health systems. Adjacent in polygenic and pharmacogenomic reporting, with strong enterprise distribution that Genomes.io's Virtual Labs is targeting.
- LunaDNA: Community-owned genomic and health-data sharing platform that compensates members via shares for data contribution. Conceptually aligned with Genomes.io's user-owned-data and token-reward model, making it a comparable decentralized data-network play.
- EncrypGen: Blockchain-based genomic data marketplace where researchers pay DNA holders for access to their data. Closely comparable token-incentivized data-sharing model and competitor in the decentralized-genomics-for-research category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
genomes.io social profiles
Digital presencegenomes.io compliance and trust
Trust signalCompliance4 records
genomes.io financial estimates
Financial estimateRevenue estimate
Valuation estimate
genomes.io leadership team
Management profileNumber of profiles
Profiles3 records
genomes.io funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
genomes.io M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about genomes.io
What does genomes.io do?
Genomes.io operates a decentralized genomic data platform that lets individuals store, manage, and monetize their DNA through SEV-ES encrypted vaults. Users can either purchase 30x whole genome sequencing through partner labs or upload existing raw DNA files from 23andMe, MyHeritage, or Ancestry.com. Pharmaceutical, biotech, and academic organizations access verified, consent-based genomic datasets through the Virtual Labs portal to run research studies against encrypted, user-owned data.
Is genomes.io a public or private company?
genomes.io is a private company. It is classified as venture growth investor backed and is currently operating.
When was genomes.io founded?
genomes.io was founded in 2018. It employs 11 to 50 people.
Where is genomes.io based?
genomes.io is headquartered in London, United Kingdom, in the Europe region.
How does genomes.io make money?
Five revenue lines are on record. DNA Sequencing Kit Sales are the primary driver. The others are lifetime Subscription for Reports, $GENOME Token Rewards, $KIT Staking Program and virtual Lab Enterprise Services.
Who are genomes.io's main competitors?
Direct peers on record are Nebula Genomics, Dante Genomics, Veritas Genetics and Sequencing.com. Broad incumbents are 23andMe, Ancestry.com and MyHeritage. Emerging players are Color Genomics, LunaDNA and EncrypGen.
Does genomes.io have an API?
No public API is recorded for genomes.io.
What industry is genomes.io in?
genomes.io's product category is Genomic Data Platform. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 2835.